(XYL) Xylem - NYSE
Sector: Industrials | Industry: Specialty Industrial Machinery | Exchange: NYSE (USA) | Market Cap: 26.629m USD | Total Return: -10.9% in 12m
Avg Turnover: 195M
EPS Trend: 99.7%
Qual. Beats: 0
Rev. Trend: 89.3%
Qual. Beats: 0
Warnings
Below Avwap Earnings
Tailwinds
No distinct edge detected
Xylem Inc. (XYL) is a global provider of engineered water technology solutions, operating across four primary segments: Water Infrastructure, Applied Water, Measurement and Control Solutions, and Water Solutions and Services. The company designs and manufactures a broad portfolio of pumps, filtration systems, and biological treatment equipment for utility, industrial, and residential applications. Its brand portfolio includes established names such as Flygt, Goulds Water Technology, and Sensus.
The business model increasingly integrates digital smart water technology, utilizing sensors, data analytics, and cloud-based monitoring to improve infrastructure efficiency. This alignment with the Industrial Machinery sector reflects a broader industry shift toward automated resource management and predictive maintenance. For a deeper look at the companys fundamentals, ValueRay provides additional analytical tools.
Headquartered in Washington, D.C., Xylem also provides extensive aftermarket support, including preventative maintenance, mobile dewatering rentals, and asset management services. These recurring service models help mitigate the cyclicality often associated with large-scale industrial equipment manufacturing.
- Aging municipal infrastructure upgrades drive sustained demand for water treatment solutions
- Municipal utility budget cycles influence long-term revenue growth and project backlogs
- Smart meter adoption and digital water analytics expand high-margin recurring revenue
- Industrial and commercial capital expenditure levels impact demand for water management systems
- Global environmental regulations and water scarcity concerns accelerate demand for filtration technology
| Net Income: 973.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.06 > 0.02 and ΔFCF/TA 0.33 > 1.0 |
| NWC/Revenue: 14.02% < 20% (prev 22.31%; Δ -8.29% < -1%) |
| CFO/TA 0.08 > 3% & CFO 1.32b > Net Income 973.0m |
| Net Debt (1.38b) to EBITDA (1.80b): 0.76 < 3 |
| Current Ratio: 1.46 > 1.5 & < 3 |
| Outstanding Shares: last quarter (243.4m) vs 12m ago -0.18% < -2% |
| Gross Margin: 38.61% > 18% (prev 37.54%; Δ 1.07% > 0.5%) |
| Asset Turnover: 54.25% > 50% (prev 51.92%; Δ 2.34% > 0%) |
| Interest Coverage Ratio: 49.32 > 6 (EBIT TTM 1.23b / Interest Expense TTM 25.0m) |
| A: 0.08 (Total Current Assets 4.03b - Total Current Liabilities 2.75b) / Total Assets 17.0b |
| B: 0.22 (Retained Earnings 3.79b / Total Assets 17.0b) |
| C: 0.07 (EBIT TTM 1.23b / Avg Total Assets 16.8b) |
| D: 1.92 (Book Value of Equity 11.0b / Total Liabilities 5.72b) |
| Altman-Z'' = 3.73 = AA |
| DSRI: 0.97 (Receivables 1.80b/1.74b, Revenue 9.09b/8.60b) |
| GMI: 0.97 (GM 37.54% / 38.61%) |
| AQI: 1.02 (AQ_t 0.69 / AQ_t-1 0.68) |
| SGI: 1.06 (Revenue 9.09b / 8.60b) |
| TATA: -0.02 (NI 973.0m - CFO 1.32b) / TA 17.0b) |
| Beneish M = -3.02 (Cap -4..+1) = AA |
As of June 18, 2026, the stock is trading at USD 110.29 with a total of 2,084,849 shares traded.
Over the past week, the price has changed by +2.95%,
over one month by +2.24%,
over three months by -9.07% and
over the past year by -10.89%.
Xylem has received a consensus analysts rating of 4.05. Therefore, it is recommended to buy XYL.
- StrongBuy: 9
- Buy: 5
- Hold: 8
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 150.7 | 36.6% |
P/E Trailing = 27.8682
P/E Forward = 20.202
P/S = 2.9291
P/B = 2.427
P/EG = 1.5894
Revenue TTM = 9.09b USD
EBIT TTM = 1.23b USD
EBITDA TTM = 1.80b USD
Long Term Debt = 1.41b USD (from longTermDebt, last quarter)
Short Term Debt = 654.0m USD (from shortTermDebt, last quarter)
Debt = 2.18b USD (from shortLongTermDebtTotal, last quarter) + Leases 123.0m
Net Debt = 1.38b USD (calculated: Debt 2.18b - CCE 808.0m)
Enterprise Value = 28.0b USD (26.6b + Debt 2.18b - CCE 808.0m)
Interest Coverage Ratio = 49.32 (Ebit TTM 1.23b / Interest Expense TTM 25.0m)
EV/FCF = 28.99x (Enterprise Value 28.0b / FCF TTM 966.0m)
FCF Yield = 3.45% (FCF TTM 966.0m / Enterprise Value 28.0b)
FCF Margin = 10.63% (FCF TTM 966.0m / Revenue TTM 9.09b)
Net Margin = 10.70% (Net Income TTM 973.0m / Revenue TTM 9.09b)
Gross Margin = 38.61% ((Revenue TTM 9.09b - Cost of Revenue TTM 5.58b) / Revenue TTM)
Gross Margin QoQ = 37.79% (prev 38.88%)
Tobins Q-Ratio = 1.65 (Enterprise Value 28.0b / Total Assets 17.0b)
Interest Expense / Debt = 1.14% (Interest Expense 25.0m / Debt 2.18b)
Taxrate = 19.54% (236.0m / 1.21b)
NOPAT = 992.1m (EBIT 1.23b * (1 - 19.54%))
Current Ratio = 1.46 (Total Current Assets 4.03b / Total Current Liabilities 2.75b)
Debt / Equity = 0.20 (Debt 2.18b / totalStockholderEquity, last quarter 11.0b)
Debt / EBITDA = 0.76 (Net Debt 1.38b / EBITDA 1.80b)
Debt / FCF = 1.42 (Net Debt 1.38b / FCF TTM 966.0m)
Total Stockholder Equity = 11.2b (last 4 quarters mean from totalStockholderEquity)
RoA = 5.81% (Net Income 973.0m / Total Assets 17.0b)
RoE = 8.70% (Net Income TTM 973.0m / Total Stockholder Equity 11.2b)
RoCE = 9.79% (EBIT 1.23b / Capital Employed (Equity 11.2b + L.T.Debt 1.41b))
RoIC = 6.89% (NOPAT 992.1m / Invested Capital 14.4b)
WACC = 8.26% (E(26.6b)/V(28.8b) * Re(8.86%) + D(2.18b)/V(28.8b) * Rd(1.14%) * (1-Tc(0.20)))
Discount Rate = 8.86% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 62.93 | Cagr: 0.34%
[DCF] Terminal Value 76.51% ; FCFF base≈935.2m ; Y1≈1.01b ; Y5≈1.22b
[DCF] Fair Price = 73.20 (EV 18.8b - Net Debt 1.38b = Equity 17.4b / Shares 237.7m; r=8.35% [WACC [floored]]; 5y FCF grow 8.66% → 2.50% )
EPS Correlation: 99.75 | EPS CAGR: 16.28% | SUE: 0.84 | # QB: 0
Revenue Correlation: 89.31 | Revenue CAGR: 13.36% | SUE: 0.31 | # QB: 0
EPS current Quarter (2026-06-30): EPS=1.34 | Chg30d=+0.00% | Revisions=-56% | Analysts=19
EPS next Quarter (2026-09-30): EPS=1.46 | Chg30d=+0.14% | Revisions=+18% | Analysts=19
EPS current Year (2026-12-31): EPS=5.53 | Chg30d=+0.05% | Revisions=+43% | GrowthEPS=+8.9% | GrowthRev=+2.4%
EPS next Year (2027-12-31): EPS=6.09 | Chg30d=+0.12% | Revisions=-14% | GrowthEPS=+10.2% | GrowthRev=+3.9%
[Analyst] Revisions Ratio: -56%